EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Ifosfamide, cisplatin, and 13-Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: A phase I-II study



Ifosfamide, cisplatin, and 13-Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: A phase I-II study



Cancer 92(4): 814-821, August 15



BACKGROUND: Ifosfamide (IFO) and cisplatin (CDDP) are active drugs in the treatment of patients with squamous cell carcinoma (SCC) of the head and neck. 13-Cis retinoic acid (RA), along with its antiproliferative and differentiating activity on SCC cell lines, has immunomodulatory and chemopreventive effects. The objective of the current Phase I-II study was to evaluate the combination of CDDP, IFO, and RA in patients with advanced or recurrent SCC of the head and neck. METHODS: Patients with measurable recurrent, metastatic, or locally advanced SCC of the head and neck were eligible. Patients received a fixed dose of 20 mg/m2 CDDP, and IFO was administered with sodium mercaptoethanesolfonate in three-dose increments (1000 mg/m2, 1200 mg/m2, and 1500 mg/m2) up to dose limiting toxicity. Both drugs were given for 5 consecutive days every 3 weeks. RA (0.5 mg/kg) was given orally for 5 days per week. RESULTS: Fifty-two patients either with locoregional recurrence or distant metastases (50%) or with locally advanced SCC of the head and neck beyond surgery or radiation therapy (50%) were entered into the trial. Fifteen patients were enrolled in the Phase I study, during which the maximum tolerated dose of IFO was 1500 mg/m2. In the Phase II study (CDDP 20 mg/m2 and IFO 1200 mg/m2), the response rate was 72% (95% confidence interval, 57-83%). After a median follow-up of 23 months, the median time to disease progression was 10.4 months (range, 2.9-47.2+ months), and the median overall survival was 12.95 months (range, 1.7-47.2+ months). Two patients were converted from a partial response to a complete response with RA. Toxicity was relatively well tolerated and caused no deaths. Grade 3-4 neutropenia was observed in 16 patients, and Grade 2-3 diarrhea toxicity occurred in 9 patients. CONCLUSIONS: The dose and schedule for the combination of CDDP, IFO, and RA that were used in this study are feasible and active in the treatment of patients with SCC of the head and neck, with durable responses and a relatively well tolerated toxicity.

(PDF emailed within 0-6 h: $19.90)

Accession: 010791195

Download citation: RISBibTeXText

PMID: 11550152

DOI: 10.1002/1097-0142(20010815)92:4<814::aid-cncr1387>3.0.co;2-8



Related references

Phase I-II study of docetaxel, ifosfamide, cisplatin and 13-cis retinoic acid in locally advanced or recurrent squamous cell carcinoma of the head and neck. Proceedings of the American Association for Cancer Research Annual Meeting 44: 1060-1061, July, 2003

Ifosfamide cisplatin and 13-cis retinoic acid in the treatment of advanced squamous cell carcinoma of the head and neck A phase II study. Proceedings of the American Association for Cancer Research Annual Meeting 40: 190, March, 1999

Phase II study of a combination of low-dose cisplatin with 13-cis-retinoic acid and interferon-alpha in patients with advanced head and neck squamous cell carcinoma. Anti-Cancer Drugs 10(4): 369-374, 1999

Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. Journal of Clinical Oncology 16(4): 1325-1330, 1998

Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study. Oncology Reports 5(6): 1499-1505, 1998

Phase II study of high-dose ifosfamide as a single agent and in combination with cisplatin in the treatment of advanced and/or recurrent squamous cell carcinoma of head and neck. Oncology (Basel) 50(2): 86-91, 1993

A phase II study of vinorelbine , cisplatin and 5-fluorouracil in patients with locally advanced recurrent, and/or metastatic squamous cell carcinoma of the head and neck. European Journal of Cancer 35(SUPPL 4): S176, Sept, 1999

Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck. Seminars in Oncology 22(5 Suppl 12): 22-25, 1995

A study using ifosfamide and etoposide in patients with cisplatin-refractory recurrent or metastatic head and neck squamous cell carcinoma. Japanese Journal of Clinical Oncology 41(5): 630-636, 2011

A phase II study of levofolinic acid and 5-fluorouracil plus cisplatin in patients with advanced head and neck squamous cell carcinoma. Oncology 50(6): 490-494, 1993

Phase I/II study of docetaxel, cisplatin and S-1 in locally advanced, recurrent and metastatic head and neck squamous cell carcinoma. Oncology Letters 4(5): 898-904, 2012

Phase ii study of high dose ifosfamide as a single agent or in combination chemotherapy in the treatment of advanced and or recurrent squamous cell carcinoma of the head and neck. Journal of Cancer Research & Clinical Oncology 116(SUPPL PART 1): 701, 1990

A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007. Cancer 107(2): 319-327, 2006